Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in three major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 13, 2024 at 2:00 PM EST, the 7th Annual Evercore HealthCONx Conference on December 4, 2024 at 9:35 AM EST, and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 8:30 AM EST. All presentations will be available via live webcast through Madrigal's Investor Relations Events page.
Details
News Market Reaction – MDGL
The recorded move for MDGL in the trading session of this news was +0.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
UBS Global Healthcare Conference 2024
Wednesday, November 13, 2024 at 2:00 P.M. EST
The presentation will be webcast live and may be accessed here.
7th Annual Evercore HealthCONx Conference
Wednesday, December 4, 2024 at 9:35 A.M. EST
Piper Sandler 36th Annual Healthcare Conference
Thursday, December 5, 2024 at 8:30 A.M. EST
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.